BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved targeted cancer therapies – BlossomHill combines a deep understanding of disease and protein dynamics with its structure-based rational drug design expertise to identify the specific structural liabilities that limit existing therapies or approaches, and then design novel chemical scaffolds to directly address these limitations. The company’s initial development efforts are focused on its two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR™ inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with an initial development focus in the C797S resistance population after 3ʳᵈ generation EGFR TKI treatment; BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being developed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS); and BH-501284, our pre-clinical, non-covalent, selective, pan-KRAS Switch II inhibitor that leverages a novel chemical scaffold to selectively target and modulate activated KRAS.
